07 jun: Bear Stearns, Ex-Executives, Agree to Settle Shareholder Suit for..
07 jun: ECB Foreign Exchange Reference Rates - Jun 07
07-06-2012 14:57:00

PRESS RELEASE: Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Powerful New Certegra(R) Informatics Workstation launched at SIIM 2012

Intended for U.S. Media Only

PR Newswire

TARRYTOWN, N.Y., June 7, 2012

TARRYTOWN, N.Y., June 7, 2012 /PRNewswire/ -- Bayer Radiology & Interventional announced the introduction of the Certegra(R) Workstation, an informatics-driven, touch--screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management(TM) applications and a new P3T(R) 2.0 operating environment. The new Workstation will be presented at the annual meeting of the Society for Imaging Informatics in Medicine (SIIM) 2012 June 7 - 12 in Orlando, FL. Following the initial launch in the U.S. and Canada, the Workstation will be rolled out in phases in markets around the world.

The Workstation serves as a single interface for radiology technologists, enabling them to provide improved patient care from study set-up and preparation to administration of the patient's study. It will be the cornerstone of Bayer's industry-first[1] Contrast Dose Management solution and informatics platform. In establishing and uploading the patient's contrast-injection record, the Workstation imports patient data directly from the Modality Work List -- reducing manual entry errors to the patient record.

"Today's technology-driven CT suite demands timely access to reliable contrast-dose records throughout the chain of care," said Anthony Cinalli, vice president of the informatics business at Bayer Radiology & Interventional. "Enabling a single workflow-centralized interface, the Workstation allows for fewer clicks, less manual entry and greater control over the quality and consistency of patient care."

Interfacing with Medrad Stellant(R) CT injection systems, the Workstation's comprehensive suite of software options provides physicians and healthcare professionals instant access to real-time actionable CT contrast data captured at the point of care enabling benefits including:

-- Reduce sub-diagnostic studies, unnecessary rescans and associated

radiation exposure[2] [3],(P3T 2.0 for personalized CT abdominal, cardiac

and pulmonary angiography studies)

-- Enable more complete diagnostic decisions (PACS Outbound Interface)

-- Speed-up radiology report turnaround time and create greater study-volume

bandwidth (RIS and SR Outbound Interfaces)

-- Improve department performance by trending, reporting and analyzing

actionable data with pinpoint accuracy (Informatics Starter Package, and

the Data Analysis and Reporting Tool)

Bayer HealthCare will have the Certegra(R) Workstation on display at its booth at SIIM 2012 (booth #217 - 221).

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

[1] Reference on file.

[2] Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible, MD, PhD. Study supported by MEDRAD Inc.

[3] 510(k) FDA clearance number: K082905

SOURCE Bayer HealthCare

/CONTACT: Karen Sutherland, +1-973-487-2113, karen.sutherland@bayer.com or Alicia Cafardi, +1-724-940-8621, alicia.cafardi@bayer.com

/Web site: http://www.bayerhealthcare.com/

(END) Dow Jones Newswires

June 07, 2012 08:57 ET (12:57 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 nov
VWS
Hejsa Mena.  nu har jeg observeret at du kommer i meget spændende diagologer med de fleste skribente..
42
23 nov
OW
Thomas Eriksson, som er chef for investeringsbanken Carnegie, er blevet kontaktet af Finansinspektio..
34
27 nov
 
Noget af det sværeste og mest risikofyldte i investeringsuniverset er at investere i turn-arounds. A..
26
26 nov
OW
  Carnegie er gå i offensiven de sidste par dage omkring deres rolle i OW Bunker sagen.  Flere medie..
24
22 nov
VWS
tauser, det korte svar er:......................................................................... ..
22
26 nov
VWS
@MENA .. dit indlæg giver ikke mening i forhold til diskussionen. Men som sædvanlig kommenterer du f..
21
27 nov
BAVA
Hermed mit første indlæg som nok bliver et lidt længere et af slagsen. Har fulgt Bavarian Nordic med..
19
26 nov
VWS
Du burde forvises fra dette forum. Hold kæft hvor er du trættende at høre på!! Du skal nedgøre alt o..
16
21 nov
SAS-DKK
Jeg har i de sidste par måneder kikket lidt nærmere på SAS. Årsagen til min nysgerrighed skyldes;   ..
16
23 nov
OW
Jeg er stadig af den holdning at Altor burde betale samtlige 3 mia. kr. tilbage som de har fået af O..
14

Aktier/åbning: Billig olie sender Mærsk til bunden i rødt C20

28-11-2014 09:17:10
Det danske aktiemarked har fredag lagt svagt fra land. C20 Cap falder efter kort tid handel med 0,7 pct. til indeks 814,55. Torsdag endte C20 Cap-indekset margi..

Aktier/tendens: Forsat prisfald for olien sender Mærsk i fokus

28-11-2014 08:26:24
Det danske aktiemarked ventes fredag at lægge roligt ud, efter at C20 Cap-indekset torsdag i handlens døende minutter vendte på en tallerken og endte dagen med ..

Roblon opjusterer resultatforventningerne til helåret - NY

27-11-2014 15:45:05
Efter at være blevet forelagt de foreløbige regnskabstal for regnskabsåret 2013/14 har bestyrelsen i Roblon fundet anledning til at justere på forventningerne t..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Forsat prisfald for olien sender Mærsk i fokus
2
Mærsk/Berenberg: Alt for billig - potentiale på cirka 50 pct
3
Carlsberg: Rubelstorm øget til næsten orkan
4
Aktier/middag: Vestas, Carlsberg og Mærsk glider i olien
5
USA: Amerikansk aktiemarked lukket på grund af Thanksgiving
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. november 2014 14:22:13
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141127.2 - EUROWEB4 - 2014-11-28 14:22:13 - 2014-11-28 14:22:13 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x